Literature DB >> 10330276

Cell spreading distinguishes the mechanism of augmentation of T cell activation by integrin-associated protein/CD47 and CD28.

M I Reinhold1, J M Green, F P Lindberg, M Ticchioni, E J Brown.   

Abstract

Integrin-associated protein (IAP/CD47) is a 50 kDa transmembrane protein initially defined as a regulator of beta3 integrin-mediated functions in neutrophils. IAP also can synergize with the TCR in T cell activation independent of beta3 integrins. To analyze the mechanism for IAP synergy with TCR, we expressed in Jurkat cells a chimeric molecule, consisting of the CD16 extracellular domain, the CD7 transmembrane domain and the TCR zeta chain cytoplasmic tail (CD16-7-zeta), which on its own is unable to induce IL-2 production. Ligation of IAP acted in synergy with TCR to induce IL-2 transcription and synthesis, but failed to synergize with the signal generated by CD16-7-zeta, while CD28 was a potent co-stimulator with both TCR and CD16-7-zeta. The failure of IAP to activate Jurkat together with CD16-7-zeta correlated with a lack of c-Jun N-terminal kinase, but not extracellular-signal-regulated kinase activation. Jurkat adhesion to anti-IAP, but not anti-CD28, induced cell spreading and the same domains of IAP required for augmentation of T cell activation were required to induce cell spreading. IAP synergy with TCR signaling likely results from its ability to stimulate adhesion to a ligand-expressing surface or antigen-presenting cell (APC), rather than from initiation of a novel signaling cascade. We conclude that a major role for ligation of IAP in T cell activation is to enhance the efficiency of TCR signaling by causing T cells to spread on an APC or surface.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10330276     DOI: 10.1093/intimm/11.5.707

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  24 in total

1.  CD47 Receptor Globally Regulates Metabolic Pathways That Control Resistance to Ionizing Radiation.

Authors:  Thomas W Miller; David R Soto-Pantoja; Anthony L Schwartz; John M Sipes; William G DeGraff; Lisa A Ridnour; David A Wink; David D Roberts
Journal:  J Biol Chem       Date:  2015-08-26       Impact factor: 5.157

2.  NOS Inhibition Modulates Immune Polarization and Improves Radiation-Induced Tumor Growth Delay.

Authors:  Lisa A Ridnour; Robert Y S Cheng; Jonathan M Weiss; Sukhbir Kaur; David R Soto-Pantoja; Debashree Basudhar; Julie L Heinecke; C Andrew Stewart; William DeGraff; Anastasia L Sowers; Angela Thetford; Aparna H Kesarwala; David D Roberts; Howard A Young; James B Mitchell; Giorgio Trinchieri; Robert H Wiltrout; David A Wink
Journal:  Cancer Res       Date:  2015-05-19       Impact factor: 12.701

3.  Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1.

Authors:  Sukhbir Kaur; Svetlana A Kuznetsova; Michael L Pendrak; John M Sipes; Martin J Romeo; Zhuqing Li; Lijuan Zhang; David D Roberts
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

4.  CD47 deficiency confers cell and tissue radioprotection by activation of autophagy.

Authors:  David R Soto-Pantoja; Thomas W Miller; Michael L Pendrak; William G DeGraff; Camille Sullivan; Lisa A Ridnour; Mones Abu-Asab; David A Wink; Maria Tsokos; David D Roberts
Journal:  Autophagy       Date:  2012-08-09       Impact factor: 16.016

5.  Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation.

Authors:  Thomas W Miller; Sukhbir Kaur; Kelly Ivins-O'Keefe; David D Roberts
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

Review 6.  Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47.

Authors:  David R Soto-Pantoja; Erica V Stein; Natasha M Rogers; Maryam Sharifi-Sanjani; Jeffrey S Isenberg; David D Roberts
Journal:  Expert Opin Ther Targets       Date:  2012-10-27       Impact factor: 6.902

7.  CD47 signaling regulates the immunosuppressive activity of VEGF in T cells.

Authors:  Sukhbir Kaur; Tiffany Chang; Satya P Singh; Langston Lim; Poonam Mannan; Susan H Garfield; Michael L Pendrak; David R Soto-Pantoja; Avi Z Rosenberg; Shelly Jin; David D Roberts
Journal:  J Immunol       Date:  2014-09-08       Impact factor: 5.422

Review 8.  CD47: a potential immunotherapy target for eliminating cancer cells.

Authors:  F Kong; F Gao; H Li; H Liu; Y Zhang; R Zheng; Y Zhang; J Chen; X Li; G Liu; Y Jia
Journal:  Clin Transl Oncol       Date:  2016-02-01       Impact factor: 3.405

9.  Blockade of CD47 increases survival of mice exposed to lethal total body irradiation.

Authors:  David R Soto-Pantoja; Lisa A Ridnour; David A Wink; David D Roberts
Journal:  Sci Rep       Date:  2013-01-08       Impact factor: 4.379

10.  Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors.

Authors:  Sukhbir Kaur; David R Soto-Pantoja; Erica V Stein; Chengyu Liu; Abdel G Elkahloun; Michael L Pendrak; Alina Nicolae; Satya P Singh; Zuqin Nie; David Levens; Jeffrey S Isenberg; David D Roberts
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.